China

Pfizer infuses $200M into CStone, scoring a second PD-L1 and outlining a sprawling China pact
Pfizer infuses $200M into CStone, scoring a second PD-L1 and outlining a sprawling China pact
Endpoints
Pfizer
China
CStone
cancer
Flag link:
Racing ahead of Merck and Innovent, Junshi declares PhIII success on cancer that won them 'breakthrough' status
Racing ahead of Merck and Innovent, Junshi declares PhIII success on cancer that won them 'breakthrough' status
Endpoints
Junshi Biosciences
China
Merck
Innovent
nasopharyngeal carcinoma
toripalimab
Flag link:
China’s Junshi hits immuno-oncology milestone with breakthrough designation from FDA
China’s Junshi hits immuno-oncology milestone with breakthrough designation from FDA
MedCity News
China
Junshi Biosciences
immuno-oncology
toripalimab
nasopharyngeal carcinoma
FDA
Flag link:
Chinese drug firm says thousands have been vaccinated for COVID-19 on an emergency use scheme
Chinese drug firm says thousands have been vaccinated for COVID-19 on an emergency use scheme
Pharmafile
China
vaccines
COVID-19
Flag link:
Lilly Asia Ventures leads AstraZeneca spinout's $100M push into China's growing R&D hub in Wuxi
Lilly Asia Ventures leads AstraZeneca spinout's $100M push into China's growing R&D hub in Wuxi
Endpoints
Eli Lilly
Lilly Asia Ventures
AstraZeneca
China
R&D
Dizal Pharmaceutical
Flag link:
How Is Medtech Impacted by a Strained US-China Relationship? A CEO Speaks Out
How Is Medtech Impacted by a Strained US-China Relationship? A CEO Speaks Out
Medical Devices and Diagnostics Industry
China
devices
Medtech
Todos Medical
Flag link:
Eli Lilly Strikes $1 Billion Deal with Innovent for Checkpoint Inhibitor
Eli Lilly Strikes $1 Billion Deal with Innovent for Checkpoint Inhibitor
BioSpace
Eli Lilly
Innovent Biologics
China
immuno-oncology
Flag link:
Chinese regulators pen requirements for COVID-19 vaccine approval—and they're stricter than the FDA's
Chinese regulators pen requirements for COVID-19 vaccine approval—and they're stricter than the FDA's
Fierce Pharma
China
COVID-19
vaccines
drug development
Flag link:
WCLC: Lilly, Innovent tout Tyvyt front-line lung cancer win. Can it challenge Merck’s Keytruda?
WCLC: Lilly, Innovent tout Tyvyt front-line lung cancer win. Can it challenge Merck’s Keytruda?
Fierce Pharma
Eli Lilly
Innovent Biologics
China
non-small cell lung cancer
Tyvyt
Merck
Keytruda
Flag link:
AstraZeneca in first COVID-19 vaccine deal with Chinese company
AstraZeneca in first COVID-19 vaccine deal with Chinese company
Reuters
AstraZeneca
China
COVID-19
vaccines
Shenzhen Kangtai Biological
Flag link:
Bayer's Eylea shows pandemic resilience, but major China price cut drags on business
Bayer's Eylea shows pandemic resilience, but major China price cut drags on business
Fierce Pharma
Bayer
earnings
China
pandemic
COVID-19
Eylea
Flag link:
Report: China-Linked Hackers Targeted Coronavirus Vaccine Developer Moderna
Report: China-Linked Hackers Targeted Coronavirus Vaccine Developer Moderna
Motley Fool
China
hacking
Moderna Therapeutics
vaccines
mRNA 1273
Flag link:
J&J Vision debuts new try-it augmented reality tech application for Acuvue lenses in China
J&J Vision debuts new try-it augmented reality tech application for Acuvue lenses in China
Fierce Pharma
JNJ Vision
JNJ
augmented reality
China
Acuvue
contact lens
Flag link:
DOJ Charges Chinese Hackers With Trying To Steal Coronavirus Research As Part Of Decade-Long Intrusion Campaign
DOJ Charges Chinese Hackers With Trying To Steal Coronavirus Research As Part Of Decade-Long Intrusion Campaign
Forbes
China
cybersecurity
hacking
vaccines
DOJ
COVID-19
coronavirus
Flag link:
CanSino coronavirus vaccine clears mid-stage test, but data show its limits
CanSino coronavirus vaccine clears mid-stage test, but data show its limits
BioPharma Dive
China
vaccines
clinical trials
Cansino Biologics
COVID-19
Flag link:
BeiGene expands pipeline and hops on board a quest to cure hep B, inking a $540M deal with a fellow upstart biotech
BeiGene expands pipeline and hops on board a quest to cure hep B, inking a $540M deal with a fellow upstart biotech
Endpoints
China
BeiGene
Assembly Biosciences
hepatitis B
Flag link:
China's CRO powerhouse Tigermed to seek $1B IPO in Hong Kong — report
China's CRO powerhouse Tigermed to seek $1B IPO in Hong Kong — report
Endpoints
China
Hong Kong
Hangzhou Tigermed
CRO
biotech
IPOs
Flag link:
Can – and Should – Pharma Manufacturing Heed Calls to Come Home?
Can – and Should – Pharma Manufacturing Heed Calls to Come Home?
BioSpace
drug manufacturing
China
COVID-19
pandemic
Flag link:
Chinese Biotech Beigene to Raise $2.1 Billion in Share Sale
Chinese Biotech Beigene to Raise $2.1 Billion in Share Sale
Bloomberg
China
BeiGene
Amgen
NASDAQ
Flag link:
Boehringer creates Shanghai hub to connect with Chinese R&D groups
Boehringer creates Shanghai hub to connect with Chinese R&D groups
Fierce Biotech
Boehringer Ingelheim
China
Shanghai
R&D
Flag link:

Pages